Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
$5.76
$0.09(1.92%)
At close: 4:00 PM EST
$5.76
$0.09(1.92%)
Day’s Range― - ―
52-Week Range$2.94 - $6.95
Previous CloseN/A
Volume24.60K
Average Volume (3M)157.41K
Market Cap
$337.43M
Enterprise Value$269.45M
Total Cash (Recent Filing)$180.28M
Total Debt (Recent Filing)$22.53M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 05, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding58,581,604
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-5.69
Price to Sales (P/S)11.46
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue10.99
Enterprise Value/Gross Profit74.52
Enterprise Value/Ebitda-3.48
Forecast
1Y Price Target
$11.50Price Target Upside99.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$34.93M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentIncreased clinical site activity for the lead SMARCA2 inhibitor suggests momentum toward dose expansion, indicating early signs of efficacy that could boost investor confidence.
Financial RunwayCash runway extending into 2028 supports continued clinical and preclinical work, reducing near-term financing pressure for advancement of degrader and inhibitor programs.
Strategic PartnershipA 50/50 development and cost-sharing partnership with Eli Lilly de-risks key programs and preserves capital for advancing combination strategies in non-small cell lung cancer.
Bears Say
Biomarker And Efficacy SensitivityReliance on demonstrating activity in a difficult-to-treat cohort heightens the need for precise biomarker selection, and failure to identify responsive subgroups could constrain clinical and commercial potential.
Development Timeline RiskHigh baseline disease resistance in trial participants could necessitate larger or longer studies to achieve efficacy readouts, potentially delaying development milestones.
Patient Population RiskTargeting a heavily pretreated, biologically aggressive patient population raises the clinical risk that trials may not show meaningful responses, increasing outcome uncertainty.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.94 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $337.43M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is tomorrow.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.083.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,581,604 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went up 13.314%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (99.65% Upside)
$11.50 (99.65% Upside)
Hedge Fund Trend
Increased
By 306.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.15%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.50
▲(99.65% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
9.16% Mutual Funds
2.54% Other Institutional Investors
81.85% Public Companies and
Individual Investors